Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 05, 2018

SELL
$4.08 - $7.14 $1,020 - $1,785
-250 Closed
0 $0
Q1 2018

May 09, 2018

BUY
$6.76 - $11.7 $1,690 - $2,925
250 New
250 $2,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.